Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Tal Kan"'
Autor:
Tal Kan, Moshe Giladi, Uri Weinberg, Yoram Palti, Yiftah Barsheshet, Boris Brant, Tali Voloshin, Alexandra Volodin, Lilach Koren, Anat Klein-Goldberg, Efrat Zemer-Tov, Rom Paz, Tharwat Haj Khalil, Bella Koltun, Adi Haber
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a2b4f638221c4af49d81f19a42712b89
Autor:
Yiftah Barsheshet, Tali Voloshin, Boris Brant, Gadi Cohen, Lilach Koren, Roni Blatt, Shay Cahal, Tharwat Haj Khalil, Efrat Zemer Tov, Rom Paz, Anat Klein-Goldberg, Catherine Tempel-Brami, Sara Jacobovitch, Alexandra Volodin, Tal Kan, Bella Koltun, Cfir David, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 22, p 14073 (2022)
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields induce anti-mitotic effects through the disruption of the mitotic spindle
Externí odkaz:
https://doaj.org/article/75d6fe95c1064d6088e902de12d2d100
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Immunomodulatory agents that induce antitumor immunity have great potential for treatment of cancer. We have previously shown that interleukin (IL)-31, a proinflammatory cytokine from the IL-6 family, acts as an antiangiogenic agent. Here,
Externí odkaz:
https://doaj.org/article/7d9ec16b9d2a4589b68fcef2e01d3fdd
The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 12, p 3912 (2020)
Bone marrow derived cells (BMDCs) play a wide variety of pro- and anti-tumorigenic roles in the tumor microenvironment (TME) and in the metastatic process. In response to chemotherapy, the anti-tumorigenic function of BMDCs can be enhanced due to che
Externí odkaz:
https://doaj.org/article/4b5fb97056354facb5e86dc2f760628e
Autor:
Israel Vlodavsky, Neta Ilan, Yuval Shaked, Ralph D. Sanderson, Miriam Gross-Cohen, JingJing Liu, Shi-Ming Yang, Uri Barash, Ilanit Boyango, Tal Kan, Lilach Gutter-Kapon, Udayan Bhattacharya
Suppl. Figure legends Suppl. Fig. 1. The structure of H1001, a small molecule heparanase inhibitor. H1001 inhibit heparanase activity inside and outside the cell, and attenuates cellular invasion Suppl. Fig. 2. Medium conditioned by PCT-treated macro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bbd73af06bea0074fecf9be0c57ea1e
https://doi.org/10.1158/0008-5472.22423773.v1
https://doi.org/10.1158/0008-5472.22423773.v1
Autor:
Israel Vlodavsky, Neta Ilan, Yuval Shaked, Ralph D. Sanderson, Miriam Gross-Cohen, JingJing Liu, Shi-Ming Yang, Uri Barash, Ilanit Boyango, Tal Kan, Lilach Gutter-Kapon, Udayan Bhattacharya
The emerging role of heparanase in tumor initiation, growth, metastasis, and chemoresistance is well recognized, encouraging the development of heparanase inhibitors as anticancer drugs. Unlike the function of heparanase in cancer cells, little atten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::010b772d3da80a80c39713dc30d4addf
https://doi.org/10.1158/0008-5472.c.6511578.v1
https://doi.org/10.1158/0008-5472.c.6511578.v1
Autor:
Yiftah Barsheshet, Tali Voloshin, Boris Brant, Gadi Cohen, Lilach Avigdor, Roni Blatt, Shay Cahal, Tharwat Haj Khalil, Efrat Zemer-Tov, Rom Paz, Anat Klein-Goldberg, Catherine Tempel-Brami, Sara Jacobovitch, Alexandra Volodin, Tal Kan, Bella Koltun, Cfir David, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer-Tov, Rom Paz, Lilach Koren, Kerem Wainer-Katsir, Alexandra Volodin, Bella Koltun, Boris Brant, Yiftah Barsheshet, Tal Kan, Cfir David, Tharwat Haj Khalil, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
Publikováno v:
Cancer Research. 83:4860-4860
Introduction: Tumor Treating Fields (TTFields) are electric fields that disrupt cellular processes critical for cancer cell viability and tumor progression, ultimately leading to cell death. TTFields therapy is approved for treatment of adult patient
Autor:
Bella Koltun, Tali Voloshin, Tal Kan, Cfir David, Lilach Koren, Yaara Porat, Alexandra Volodin, Noa Kaynan, Anat Klein-Goldberg, Rom Paz, Boris Brant, Yiftah Barsheshet, Efrat Zemer-Tov, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
Publikováno v:
Cancer Research. 83:1738-1738
Background: Tumor Treating Fields (TTFields) are electric fields that disrupt cellular processes critical for cancer cell viability and tumor progression, ultimately leading to cell death. In addition, application of TTFields to glioblastoma cells ha
Autor:
Shilstein, Sana1 (AUTHOR) sana.shilstein@weizmann.ac.il, Meron, Tal Kan-Cipor2 (AUTHOR), Shalev, Sariel2,3,4 (AUTHOR)
Publikováno v:
Archaeological & Anthropological Sciences. Aug2020, Vol. 12 Issue 8, p1-14. 14p.